Overview

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

Open-label phase Ib/II, multicenter, international non-comparative trial. This study is designed to determine the safety and efficacy of the novel salvage regimen (CBd) followed by a carfilzomib maintenance in patients with relapsed or refractory multiple myeloma. Patients will be evaluated at scheduled visits in up to 4 study periods: pretreatment, treatment, maintenance and long-term follow-up (LTFU).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

European Myeloma Network
Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators:

Fondazione EMN Italy Onlus
Fondazione Neoplasie Sangue Onlus

Treatments:

BB 1101
Bendamustine Hydrochloride
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate